Heba Bakri, Consultant of Clinical Oncology at Assiut University, shared a post on LinkedIn:
“It was an honor to welcome Dr. Raffat Abdelfattah and the Haematology team from Assiut University for a rich and insightful discussion on the management of multiple myeloma in the era of anti-CD38 therapy, particularly Daratumumab.
The exchange of experiences across departments and the spirit of collaboration remain essential to advancing patient care.
I had the pleasure of presenting: Practical tips for the use of Daratumumab from pharmacodynamics and kinetics perspectives”
More posts featuring Heba Bakri.
